JP2008500802A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008500802A5 JP2008500802A5 JP2006518230A JP2006518230A JP2008500802A5 JP 2008500802 A5 JP2008500802 A5 JP 2008500802A5 JP 2006518230 A JP2006518230 A JP 2006518230A JP 2006518230 A JP2006518230 A JP 2006518230A JP 2008500802 A5 JP2008500802 A5 JP 2008500802A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- present
- immunogenic fragment
- proteins
- kda
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 description 77
- 102000004169 proteins and genes Human genes 0.000 description 77
- 239000012634 fragment Substances 0.000 description 53
- 230000002163 immunogen Effects 0.000 description 42
- 101710149506 28 kDa protein Proteins 0.000 description 30
- 101710137943 Complement control protein C3 Proteins 0.000 description 30
- 101710152003 Suppressor of silencing P0 Proteins 0.000 description 30
- 229960005486 vaccine Drugs 0.000 description 17
- 108020004707 nucleic acids Proteins 0.000 description 15
- 102000039446 nucleic acids Human genes 0.000 description 15
- 150000007523 nucleic acids Chemical class 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 10
- 125000003275 alpha amino acid group Chemical group 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 241000223846 Babesia canis Species 0.000 description 7
- 241000223836 Babesia Species 0.000 description 6
- 201000008680 babesiosis Diseases 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 244000045947 parasite Species 0.000 description 6
- 108020004511 Recombinant DNA Proteins 0.000 description 5
- 229940031626 subunit vaccine Drugs 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 241000223840 Babesia bigemina Species 0.000 description 4
- 241000223775 Babesia caballi Species 0.000 description 4
- 241000223848 Babesia microti Species 0.000 description 4
- 241000282465 Canis Species 0.000 description 4
- 241000223838 Babesia bovis Species 0.000 description 3
- 241000414380 Babesia canis vogeli Species 0.000 description 3
- 241001466447 Babesia gibsoni Species 0.000 description 3
- 102000002067 Protein Subunits Human genes 0.000 description 3
- 108010001267 Protein Subunits Proteins 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 241000414381 Babesia canis rossi Species 0.000 description 2
- 241000675161 Babesia motasi Species 0.000 description 2
- 241000223850 Babesia ovis Species 0.000 description 2
- 241000589969 Borreliella burgdorferi Species 0.000 description 2
- 241000205706 Cystoisospora felis Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 241000125885 Entamoeba bovis Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000711798 Rabies lyssavirus Species 0.000 description 2
- 241000545125 Tetragoneuria canis Species 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 241000712083 Canine morbillivirus Species 0.000 description 1
- 241001353878 Canine parainfluenza virus Species 0.000 description 1
- 241000701931 Canine parvovirus Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241001522296 Erithacus rubecula Species 0.000 description 1
- 241000149124 Hepatozoon canis Species 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03077178.6 | 2003-07-10 | ||
| EP03077178 | 2003-07-10 | ||
| PCT/EP2004/051454 WO2005012343A1 (en) | 2003-07-10 | 2004-07-12 | Babesia vaccines |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008500802A JP2008500802A (ja) | 2008-01-17 |
| JP2008500802A5 true JP2008500802A5 (enExample) | 2011-01-27 |
| JP4887144B2 JP4887144B2 (ja) | 2012-02-29 |
Family
ID=34112460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006518230A Expired - Fee Related JP4887144B2 (ja) | 2003-07-10 | 2004-07-12 | バベシアワクチン |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7722879B2 (enExample) |
| EP (1) | EP1646647A1 (enExample) |
| JP (1) | JP4887144B2 (enExample) |
| AU (1) | AU2004260737B2 (enExample) |
| BR (1) | BRPI0412419A (enExample) |
| CA (1) | CA2531329A1 (enExample) |
| WO (1) | WO2005012343A1 (enExample) |
| ZA (1) | ZA200600180B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7682619B2 (en) | 2006-04-06 | 2010-03-23 | Cornell Research Foundation, Inc. | Canine influenza virus |
| EP2658568A1 (en) * | 2010-12-29 | 2013-11-06 | Intervet International B.V. | Canine babesiosis vaccine antigen |
| EP2626365A1 (en) * | 2012-02-10 | 2013-08-14 | MegaCor Diagnostik GmbH | Compounds and methods for the diagnosis of babesia canis canis infection |
| RU2583139C1 (ru) * | 2014-11-13 | 2016-05-10 | Федеральное государственное бюджетное научное учреждение "Прикаспийский зональный научно-исследовательский ветеринарный институт" | Способ пролонгированной химиопрофилактики пироплазмидозов крупного рогатого скота |
| DK201970598A1 (en) | 2019-09-09 | 2021-05-17 | Apple Inc | Techniques for managing display usage |
| US20230190905A1 (en) * | 2021-09-28 | 2023-06-22 | The United States Of America, As Represented By The Secretary Of Agriculture | Transmission-blocking vaccine against babesia |
| WO2025118050A1 (pt) * | 2023-12-04 | 2025-06-12 | Laboratório Bio-Vet Ltda | Antígeno vacinal quimérico com ação tríplice contra erliquiose, anaplasmose e babesiose canina, vetor de expressão, célula recombinante, composição vacinal, kit de diagnóstico, método de tratamento e uso de proteína quimérica |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE903038A1 (en) | 1989-08-23 | 1991-02-27 | Commw Scient Ind Res Org | Antigens and polypeptides derived from babesia (12d3¹antigen) |
| EP1050541A1 (en) | 1999-04-29 | 2000-11-08 | Akzo Nobel N.V. | Babesia vaccine |
| EP1268856A2 (de) * | 2000-04-07 | 2003-01-02 | Epigenomics AG | Detektion von snp's und cytosin-methylierungen |
| EP1238983A1 (en) | 2001-03-06 | 2002-09-11 | Akzo Nobel N.V. | "Babesia canis vaccine" |
-
2004
- 2004-07-12 WO PCT/EP2004/051454 patent/WO2005012343A1/en not_active Ceased
- 2004-07-12 JP JP2006518230A patent/JP4887144B2/ja not_active Expired - Fee Related
- 2004-07-12 BR BRPI0412419-7A patent/BRPI0412419A/pt not_active Application Discontinuation
- 2004-07-12 US US10/563,601 patent/US7722879B2/en not_active Expired - Fee Related
- 2004-07-12 AU AU2004260737A patent/AU2004260737B2/en not_active Ceased
- 2004-07-12 CA CA002531329A patent/CA2531329A1/en not_active Abandoned
- 2004-07-12 EP EP04741989A patent/EP1646647A1/en not_active Withdrawn
-
2006
- 2006-01-09 ZA ZA200600180A patent/ZA200600180B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111560074B (zh) | 一种基于幽门螺旋杆菌铁蛋白的新型冠状病毒s蛋白单区域亚单位纳米疫苗 | |
| Da’Dara et al. | DNA-based vaccines protect against zoonotic schistosomiasis in water buffalo | |
| CN113666990B (zh) | 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用 | |
| KR20220010478A (ko) | 기도 감염의 치료 또는 예방용 서브유닛 백신 | |
| CN105934441A (zh) | 新型sars免疫原性组合物 | |
| JP2019513377A (ja) | 安定化された可溶性融合前ｒｓｖ ｆタンパク質 | |
| JP2025507227A (ja) | 新型コロナウイルスｓ２タンパク質のｈｒ領域に由来する組換え融合タンパク質およびその使用 | |
| KR20180064158A (ko) | 구제역 바이러스의 가용성 다가 항원단백질 및 이의 용도 | |
| JP2025172875A (ja) | パラミクソウイルスおよび／またはニューモウイルスのｆタンパク質を提示する自己組織化タンパク質ナノ構造体ならびにその使用 | |
| JP2023523423A (ja) | ＳＡＲＳ－ＣｏＶ－２に対するワクチン及びその調製物 | |
| US20190201521A1 (en) | Immunogenic composition | |
| JP2008500802A5 (enExample) | ||
| CN101257917A (zh) | 针对黄病毒科病毒感染的嵌合多肽及其治疗应用 | |
| CN113801206B (zh) | 利用受体识别域诱导抗新冠病毒中和抗体的方法 | |
| Shen et al. | DNA vaccine prime and replicating vaccinia vaccine boost induce robust humoral and cellular immune responses against MERS-CoV in mice | |
| Sobczak et al. | Identifying key drivers of efficient B cell responses: on the role of T help, antigen-organization, and toll-like receptor stimulation for generating a neutralizing anti-dengue virus response | |
| CN117045782A (zh) | 一株自组装的猪冠状病毒新型纳米颗粒疫苗及其应用 | |
| WO2024093554A1 (zh) | 针对rsv的重组亚单位疫苗及其应用 | |
| Ge et al. | Fusion expression of major antigenic segment of JEV E protein-hsp70 and the identification of domain acting as adjuvant in hsp70 | |
| CN117586422A (zh) | 一种鸭坦布苏病毒核酸疫苗及应用 | |
| WO2023138333A1 (zh) | 一种重组新型冠状病毒蛋白疫苗、其制备方法和应用 | |
| Majidi et al. | Expression and Purification of Brucella spp. Lumazine Synthase Decameric Carrier in Fusion to Extracellular Domain of Influenza M2E Protein | |
| CN106986942A (zh) | 一种包含蝙蝠肝炎病毒核心蛋白的重组融合蛋白及其制备方法和应用 | |
| CN106986943A (zh) | 一种包含北极地松鼠肝炎病毒核心蛋白的重组融合蛋白及其制备方法和应用 | |
| CN104548081A (zh) | 一种含融合蛋白ctt3h的结核病亚单位疫苗及疫苗佐剂 |